Issued Patents 2021
Showing 1–12 of 12 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 11192955 | Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors | Serengulam V. Govindan | 2021-12-07 |
| 11180559 | Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies | William A. Wegener | 2021-11-23 |
| RE48751 | Immunoconjugates with an intracellularly-cleavable linkage | Serengulam V. Govindan, Sung-Ju Moon | 2021-09-28 |
| 11116846 | Antibody-drug conjugates and uses thereof | Serengulam V. Govindan | 2021-09-14 |
| 11077201 | Immunoconjugates with an intracellularly-cleavable linkage | Serengulam V. Govindan, Sung-Ju Moon | 2021-08-03 |
| 11052156 | Antibody-drug conjugates and uses thereof | Serengulam V. Govindan | 2021-07-06 |
| 11052081 | Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132) | Serengulam V. Govindan | 2021-07-06 |
| 11020489 | Immunoconjugates with an intracellularly-cleavable linkage | Serengulam V. Govindan, Sung-Ju Moon | 2021-06-01 |
| 10988539 | Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers | Thomas M. Cardillo | 2021-04-27 |
| 10954305 | Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers | Chien-Hsing Chang | 2021-03-23 |
| 10918721 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | Serengulam V. Govindan | 2021-02-16 |
| 10918734 | Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51 | Thomas M. Cardillo | 2021-02-16 |